General
Preferred name
upadacitinib
Synonyms
ABT-494 ()
Upadacitinib (ABT-494) ()
UPADACITINIB HEMIHYDRATE ()
UPADACITINIB ANHYDROUS ()
Upadacitinib tartrate ()
Upadacitinib component of abbv-599 ()
ABT-494 TARTRATE TETRAHYDRATE ()
RINVOQ ()
Rinvoq lq ()
UPADACITINIB HYDRATE ()
Upadacitinib (as hemihydrate) ()
UPADACITINIB COMPONENT OF ABBV-599 ()
P&D ID
PD048247
CAS
1310726-60-3
Tags
available
drug
drug candidate
Approved by
EMA
PMDA
FDA
First approval
2019
Drug indication
Psoriatic arthritis
Ulcerative colitis
atopic eczema
Atopic dermatitis
Crohn disease
Rheumatoid arthritis
Drug Status
approved
investigational
Max Phase
2.0
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Upadacitinib (ABT-494) is a novel second generation Janus kinase inhibitor with high JAK1 selectivity . It is being investigated for clinical activity in autoimmune diseases including rheumatoid arthritis and Crohn's disease.
DESCRIPTION
Upadacitinib (ABT-494) is a novel second generation orally active Janus kinase inhibitor with high JAK1 selectivity . It is being investigated for clinical activity in autoimmune diseases including rheumatoid arthritis and Crohn's disease.
DESCRIPTION
Upadacitinib (ABT-494) is a novel second generation orally active Janus kinase inhibitor with high JAK1 selectivity . The chemical structure is claimed as compound 1 in Abbvie's patent WO2015061665 . It was developed for potential clinical efficacy in multiple autoimmune diseases. Its first approval was for the treatment of rheumatoid arthritis .
(GtoPdb)
DESCRIPTION
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research[1][2].
PRICE
112
DESCRIPTION
On august 2019, FDA approved fedratinib to treat adults with moderately to severely active rheumatoid arthritis
(PKIDB)
DESCRIPTION
Upadacitinib is an oral selective inhibitor of tyrosine-protein kinase JAK1 and a disease-modifying antirheumatic drug. It is used in the treatment of rheumatoid arthritis to slow down disease progression.
(Enamine Bioactive Compounds)
DESCRIPTION
Upadacitinib (ABT-494) (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
19
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
EUbOPEN Chemogenomics Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
30
Molecular Weight
380.16
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
4
Aromatic Ring Count
3
cLogP
2.91
TPSA
78.32
Fraction CSP3
0.47
Chiral centers
2.0
Largest ring
6.0
QED
0.73
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
JAK
JAK1
JAK2
MOA
JAK inhibitor
Pathway
Angiogenesis
Chromatin/Epigenetic
JAK/STAT Signaling
Stem Cells
Tyrosine Kinase/Adaptors
Epigenetics
Protein Tyrosine Kinase/RTK
Stem Cell/Wnt
Recommended Cell Concentration
1 uM
Source data
